



DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration
Silver Spring MD 20993

February 3, 2022

Michelle Ryder
Lachman Consultant Services, Inc.
1600 Stewart Avenue, Suite 604
Westbury, NY 11590

Sent via email to: m.ryder@lachmanconsultants.com

Dear Petitioner:

Your submission requesting that the Commissioner of Food and Drug Administration declare that Diazepam Injection USP, 20 mg/4 mL (5 mg/mL) single dose prefilled syringe is suitable for submission as an ANDA was received and processed under CFR 10.30 by this office on 02/02/2022.

It was assigned docket number FDA-2022-P-0118. Please refer to this docket number in future correspondence on this subject with the Agency.

Also, note that the acceptance of the suitability petition for filing is a procedural matter and in no way reflects the agency's decision on the substantive merits of the petition.

Sincerely,

Dynna Bigby
Supervisory Administrative Proceedings Officer
Dockets Management Staff
FDA/Office of Operations (OO)